ResMed (NYSE:RMD) is a global medical device company specializing in the diagnosis, treatment and management of sleep-disordered breathing and other chronic respiratory conditions. The company’s product portfolio spans continuous positive airway pressure (CPAP) and bilevel devices, masks, humidifiers and ventilation solutions for both in-center and home care settings. ResMed also offers digital health platforms designed to monitor patient adherence and therapy efficacy, providing clinicians with real-time data and analytics to improve treatment outcomes.
ResMed’s flagship devices—such as the AirSense™ and AirCurve™ series—integrate advanced algorithms that automatically adjust pressure in response to patients’ breathing patterns. The company complements its hardware offerings with cloud-connected software services like AirView®, which enables remote patient monitoring, compliance reporting and telehealth consultations. This combination of devices and digital solutions positions ResMed as a leader in connected care for sleep apnea, chronic obstructive pulmonary disease (COPD) and neuromuscular disease management.
Headquartered in San Diego, California, ResMed distributes its products in more than 120 countries through a network of direct sales, distributors and strategic partnerships. The company maintains regional offices and manufacturing facilities across North America, Europe, Asia-Pacific and Latin America to support local regulatory requirements and customer service. Its global footprint allows it to address diverse healthcare systems and respond to evolving patient needs in both developed and emerging markets.
Founded in 1989 by Dr. Peter C. Farrell, ResMed has grown from a developer of advanced positive airway pressure technology into a broader digital health innovator. Michael “Mick” Farrell, who has served as President and Chief Executive Officer since 2013, leads the company’s strategic focus on integrating data analytics with respiratory care. Under his direction, ResMed continues to expand its product pipeline and invest in research and development aimed at improving patient quality of life and reducing the burden of chronic respiratory diseases.
